The following information was provided by Lyndra Therapeutics:
Lyndra Therapeutics Inc. of Watertown raised $20.3 million from seven investors as part of an offering of equity and option securities, according to a Form D dated June 7. Total amount of the offering is just over $179 million.
Last month Lyndra announced it has dosed the first participant in its pivotal clinical trial investigating oral weekly risperidone (LYN-005) for the treatment of schizophrenia and schizoaffective disorder. This is Lyndra’s lead drug candidate.
The investigational oral weekly risperidone is a unique “long-acting oral therapy” powered by Lyndra’s LYNXTM drug delivery platform, which delivers a week’s worth of medication in one oral capsule.
Lyndra completed a $60.5 Million Series C financing back in 2021.